VPRIV® (velaglucerase alfa)
(Intravenous)

Document Number: IC-0141

Last Review Date: 07/01/2019
Date of Origin: 01/01/2012

I. Length of Authorization

Coverage will be for 12 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [Pharmacy Benefit]:
   • Vpriv 400 unit powder for injection: 18 vials per 14 days

B. Max Units (per dose and over time) [Medical Benefit]:
   • 72 billable units every 14 days

III. Initial Approval Criteria

Type 1 Gaucher’s Disease †

• Patient age at least 4 years or older; AND
• Patient has a documented diagnosis of Type 1 Gaucher Disease as confirmed by beta-glucosidase leukocyte (BGL) test with significantly reduced or absent glucocerebrosidase enzyme activity; AND
• Adults only criteria (patient at least 18 years or older): Patient’s disease results in one or more of the following:
  - Anemia [hemoglobin less than or equal to 11 g/dL (women) or 12 g/dL (men)]: OR
  - Moderate to severe hepatomegaly (liver size 1.25 or more times normal) or splenomegaly (spleen size 5 or more times normal): OR
  - Skeletal disease (e.g. lesions, remodeling defects and/or deformity of long bones, osteopenia/osteoporosis, etc.): OR
  - Symptomatic disease (e.g. bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.): OR
  - Thrombocytopenia (platelet count less than or equal to 120,000/mm3): AND
• Must be used as a single agent
† FDA Approved Indication(s)

IV. **Renewal Criteria**

- Patient continues to meet the criteria in Section III: **AND**
- Disease response as indicated by one or more of the following (compared to pre-treatment baseline):
  - Improvement in symptoms (e.g. bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.)
  - Reduction in size of liver or spleen
  - Improvement in hemoglobin/anemia
  - Improvement in skeletal disease
  - Improvement in platelet counts; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include severe hypersensitivity reactions, etc.

V. **Dosage/Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1 Gaucher Disease</td>
<td>Up to 60 units/kg every other week as a 60-minute intravenous infusion</td>
</tr>
</tbody>
</table>

VI. **Billing Code/Availability Information**

**Jcode:**
- J3385 – Injection, velaglucerase alfa, 100 units: 1 billable unit = 100 units

**NDC:**
- Vpriv 400 unit powder for injection: 54092·0701·xx

VII. **References**


Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E75.22</td>
<td>Gaucher disease</td>
</tr>
</tbody>
</table>

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: [http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx](http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx). Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>